| Leonard Contardo, OD | |
|
300 Western Ave, Allston, MA 02134-1030 | |
| (617) 783-0500 | |
| (617) 783-5540 |
| Full Name | Leonard Contardo |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 44 Years |
| Location | 300 Western Ave, Allston, Massachusetts |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417911157 | NPI | - | NPPES |
| 221892 | Other | MA | MEDICARE CCN |
| 1114175916 | Other | MA | GROUP NPI# |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2873 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mcphs University | 2365682713 | 16 |
News Archive
NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
InterSystems Corporation today announced that Technology Medical Partners (T-M-Partners) has selected the InterSystems Ensemble® rapid integration and development platform for its CMS Quality Manager healthcare application. The first of many healthcare technology solutions under development by T-M-Partners, CMS Quality Manager is designed to vastly improve the data abstraction and administrative processes of reporting core measures to the Centers for Medicaid and Medicare Services (CMS).
At the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas, several studies of the effectiveness of non-X-ray techniques to evaluate Crohn's disease revealed that diagnostic strategies such as capsule endoscopy (CE) and magnetic resonance enteroscopy (MRE) are useful in managing patients with inflammatory bowel disease (IBD) and avoiding ionizing radiation.
› Verified 8 days ago
| Provider Name | Edward M Kennedy Community Health Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1609842152 PECOS PAC ID: 3476512740 Enrollment ID: O20041004000840 |
News Archive
NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
InterSystems Corporation today announced that Technology Medical Partners (T-M-Partners) has selected the InterSystems Ensemble® rapid integration and development platform for its CMS Quality Manager healthcare application. The first of many healthcare technology solutions under development by T-M-Partners, CMS Quality Manager is designed to vastly improve the data abstraction and administrative processes of reporting core measures to the Centers for Medicaid and Medicare Services (CMS).
At the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas, several studies of the effectiveness of non-X-ray techniques to evaluate Crohn's disease revealed that diagnostic strategies such as capsule endoscopy (CE) and magnetic resonance enteroscopy (MRE) are useful in managing patients with inflammatory bowel disease (IBD) and avoiding ionizing radiation.
› Verified 8 days ago
| Provider Name | Mcphs University |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1871852566 PECOS PAC ID: 2365682713 Enrollment ID: O20130708000251 |
News Archive
NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
InterSystems Corporation today announced that Technology Medical Partners (T-M-Partners) has selected the InterSystems Ensemble® rapid integration and development platform for its CMS Quality Manager healthcare application. The first of many healthcare technology solutions under development by T-M-Partners, CMS Quality Manager is designed to vastly improve the data abstraction and administrative processes of reporting core measures to the Centers for Medicaid and Medicare Services (CMS).
At the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas, several studies of the effectiveness of non-X-ray techniques to evaluate Crohn's disease revealed that diagnostic strategies such as capsule endoscopy (CE) and magnetic resonance enteroscopy (MRE) are useful in managing patients with inflammatory bowel disease (IBD) and avoiding ionizing radiation.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leonard Contardo, OD 930 Commonwealth Ave, Suite 2a, Boston, MA 02215-1274 Ph: (617) 262-2020 | Leonard Contardo, OD 300 Western Ave, Allston, MA 02134-1030 Ph: (617) 783-0500 |
News Archive
NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that WoundSource™ has highlighted NovaBay's NeutroPhase wound cleanser in a recent blog posting. The blog explains why NeutroPhase can play an important role in treating life-threatening necrotizing fasciitis, or 'flesh-eating' infections.
Maxygen, Inc., a biotechnology company, today announced that its Board of Directors has approved an increase to the company's current stock repurchase program from $10.0 million to $20.0 million. The repurchase program expires on December 31, 2011.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced the initiation of the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) study. This clinical trial is designed to evaluate the equivalence of Endoscopic Vessel Harvesting (EVH) in Coronary Artery Bypass Graft (CABG) surgery compared with historical data for open vein harvesting. David Moore, M.D., of THE HEART HOSPITAL Baylor Plano is the principal investigator for the OPTION trial.
InterSystems Corporation today announced that Technology Medical Partners (T-M-Partners) has selected the InterSystems Ensemble® rapid integration and development platform for its CMS Quality Manager healthcare application. The first of many healthcare technology solutions under development by T-M-Partners, CMS Quality Manager is designed to vastly improve the data abstraction and administrative processes of reporting core measures to the Centers for Medicaid and Medicare Services (CMS).
At the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas, several studies of the effectiveness of non-X-ray techniques to evaluate Crohn's disease revealed that diagnostic strategies such as capsule endoscopy (CE) and magnetic resonance enteroscopy (MRE) are useful in managing patients with inflammatory bowel disease (IBD) and avoiding ionizing radiation.
› Verified 8 days ago
Carol A. Weil, O.D., RPT Optometrist Medicare: Not Enrolled in Medicare Practice Location: 214 Lincoln St, Suite 205, Allston, MA 02134 Phone: 617-782-0100 Fax: 617-782-1702 | |
Dr. Mark Barry Dalins, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 214 Lincoln St., Suite 205, Allston, MA 02134 Phone: 617-782-0100 Fax: 617-782-1702 |